Guidelines of clinical practice of the SERV: Treatment of exudative age-related macular degeneration (AMD);GuÍas de prÁctica clÍnica de la SERV: Tratamiento de la degeneraciÓn macular asociada a la edad (DMAE) exudativa

Archivos de la Sociedad Espanola de Oftalmologia

Volumn 84, Issue 7, 2009, Pages 333-344

  Ruiz Moreno, J M ^a   Arias Barquet, L ^b   Armada Maresca F ^c   Boixadera Espax, A ^d   Garcia Layana A ^e   Gomez Ulla De Irazazabal F ^f   Mones Carilla J ^g   Pinerobustamante A ^h   Suarez De Figueroa M ⁱ  

^a UNIVERSITY OF CASTILLA LA MANCHA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f HOSPITAL DE CONXO   (Spain)

^g CENTRO MÉDICO TEKNON   (Spain)

^h UNIVERSITY OF SEVILLE   (Spain)

ⁱ UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Age related Macular Degeneration (AMD); Bevacizumab; Pegaptanib; Photodynamic therapy; Ranibizumab; VEGF; Verteporfin

Indexed keywords

ALGORITHM; ARTICLE; EXUDATIVE MACULAR DEGENERATION; HUMAN; PRACTICE GUIDELINE;

ALGORITHMS; HUMANS; WET MACULAR DEGENERATION;

EID: 77949743762     PISSN: 03656691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Macular photocoagulation study group. Argon laser photocoagulation for neovascular maculopathy. Fiveyears results from randomized clinical trials. Arch Ophthalmol 1991; 109: 1109-1114.
2. Macular photocoagulation study group. Argon laser photocoagulation for juxtafoveal choroidal neovasculariza-tion. Five-years results from randomized clinical trials. Arch Ophthalmol 1994; 112: 500-509.
3. Macular photocoagulation study group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trials. Arch Ophthalmol 1991; 109: 1220-1231.
4. Bhatt NS, Al-Shirawi NM, Diamond JG. Krypton laser photocoagulation of peripapillary choroidal neovascular membrane. Ophthalmic Surg Lasers 1999; 30: 56-58.
5. Lai TY, Chan WM, Lam DS. Laser photocoagulation of indocyanine green aniographically identified feeder vessels to idiopathic polypoidal choroidal vasculopathy. Am J Ophthalmol 2004; 138: 693-694.
6. Johnson TM, Glaser BM. Focal laser ablation of retinal angiomatous proliferation. Retina 2006; 26: 765-772.
7. Roth DB, Scott IU, Gloth JM, Green SN, Yarian DL, Wheatley M. Micropulsed laser photocoagulation and intravitreal triamcinolone acetonide injection for the treatment of retinal angiomatous proliferation. Retina 2007; 27: 1201-1204.
8. Merrill PT, LoRusso FJ, Lomeo MD, Saxe SJ, Khan MM, Lambert HM. Surgical removal of subfoveal choroidal neovascularization in age-related macular degeneration. Ophthalmology 1999; 106: 782-789.
9. Kokame GT, Yamaoka S. Subretinal surgery for peripapi-llary subretinal neovascular membranes. Retina 2005; 25: 564-569.
10. Treatment of age-related macular degeneration with pho-todynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 1999; 117: 1329-1345. Erratum in: Arch Ophthalmol 2000; 118: 488.
11. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic Therapy of Subfoveal Choroidal Neovascu-larization in Pathologic Myopia with Verteporfin (one-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 2001; 108: 841-852.
12. Bressler NM. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovasculari-zation-verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2002; 133: 168-169.
13. Ruiz-Moreno JM, Montero J, Barile S, Zarbin M. Photody-namic therapy and high doses intravitreal triamcinolone to treat exudative age-related macular degeneration: One year outcome. Retina 2006; 26: 602-612.
14. Arias L, Garcia-Arumi J, Ramon JM, Badia M, Rubio M, Pujol O. Photodynamic therapy with intravitreal triamci-nolone in predominantly classic choroidal neovasculariza-tion: one-year results of a randomized study. Ophthalmology 2006; 113: 2243-2250.
15. Kaiser PK, TAP Study Group. Five-year results of verte-porfin therapy for subfoveal CNV due to AMD: third year of an open-label extension of the TAP Investigation. Invest Ophthalmol Vis Sci 2003; 44: E-Abstract 1099.
16. Chakravarthy U, Soubrane G, Bandello F, Chong V, Creu-zot-Garcher C, Dimitrakos SA, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol 2006; 90: 1188-1196.
17. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-2816.
18. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Ada-mis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508-1521.
19. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006; 124: 1532-1542. Erratum in: Arch Ophthalmol 2007; 125: 138.
20. Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group. Ranibizumab combined with verteporfin photody-namic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008; 145: 862-874.
21. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
22. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. Ranibizumab versus verteporfin for neovas-cular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
23. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006; 142: 660-668.
24. Kim KJ, Li B, Houck K, Winer J, Ferrara N. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 7: 53-64.
25. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999; 293: 865-881.
26. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, Miller JW, Haller JA, Reimann JD, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macu-lar degeneration. Ophthalmology 2005; 112: 1048-1053.
27. Michelle Dalton. Lucentis at one year. Eyeworld 2008-5-525 11:12:21 http://www.eyeworld.org/printarticle.php?id =4390
28. Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, et al. Anti-vascular endothelial growth factor pharma-cotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 2008; 115: 1837-1846.
29. Michels S, Rosenfeld PJ, Puliafito CA, Haraus EN, Venka-traman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005; 112: 1035-1047.
30. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005; 36: 336-339.
31. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-335.
32. Spaide R F, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-390.
33. Aisenbrey S, Ziemssen F, Volker M, Gelisken F, Szurman P, Jaissle G, et al. Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macu-lar degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 941-948.
34. Chen E, Kaiser RS, Vander J F. Intravitreal bevacizumab for refractory pigment epithelial detachment with occult choroidal neovascularization in age-related macular degeneration. Retina 2007; 27: 445-450.
35. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW J r, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495-511.
36. Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007; 27: 439-444.
37. ®): results of the Pan-American collaborative retina study group (PACORES). Graefes Arch Clin Exp Ophthalmol 2007; 246: 81-87.
38. Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer M. Intravitreal bevacizumab in the tre-atment of neovascular agerelated macular degeneration, 6-and 9-month results. Eye 2008; 22: 82-86.
39. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008; 145: 249-256.
40. Chen CY, Wong TY, Heriot WJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study. Am J Ophthalmol 2007; 143: 510-512.
41. Macular photocoagulation study group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Update findings from two clinical trials. Ophthalmology 1993; 111: 1200-1209.
42. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizu-mab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583.
43. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, et al. Randomized, doublemasked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthal-mol 2008; 145: 239-248.